These divergent trajectories underscore the unique immunological context of HBV infection, characterized by a stable expansion of exhausted and stem‐like CD8+ T cells, with implications for therapeutic strategies targeting T‐cell reinvigoration in HBV+ HCC. This evidence concerns the gene CD8A and hepatocellular carcinoma.